Hudson Robotics is introducing an advanced drug discovery technology that has been shown to identify significant lead compounds with only a tiny fraction of the expense and effort of traditional high-throughput drug screening.
advanced drug discovery technology for screening small molecules and antibodies. It is called "High Efficiency Screening" (H.E.S.), and has been shown to identify significant lead compounds with only a tiny fraction of the expense and effort of traditional high-throughput drug screening.— Hudson Robotics is introducing a novel,
Using H.E.S., researchers can, with confidence, identify the great majority of the leads against a target that may exist in a compound library, while only screening a minor portion of that library.
H.E.S. is ideal for companies or groups who don't have the budget or resources to conduct a high-throughput screen, and also need more insight into the mechanism of interaction of lead compounds with their target than would be provided by a high-throughput screen effort.
H.E.S. provides both a comprehensive identification of the significant leads in their library as well as important information about the mechanisms of leads' interactions with the target, which can greatly help to optimize those leads that are found.
High-Throughput Screening is frequently the method of choice of scientists searching a large library of molecules for those that possess a desired biological property, such as the inhibition of a key enzyme (the target) in a cellular signaling pathway. If the supporting assay is sufficiently sensitive and accurate, and if ALL the compounds in the library are screened, this approach will help the researcher find all of the active molecules that exist in that library. However, besides simply identifying a given compound as a lead, it offers no insight into why that compound interacted with the target.
This is a very costly and resource-intensive approach, and alternatives have been developed, such as virtual screens, but none of these offer enough confidence in their results to replace the more exhaustive high-throughput screen.
Hudson's H.E.S. represents a brand new approach in which, using a proprietary algorithm, only a short list of the molecules are considered. This list is then passed on to a robotic screening system where the molecules are cherry-picked and screened in the appropriate assay. The molecules that are found to be active are used to enhance the model and the process is repeated.
At the end of the process, the user will have both a list of active molecules, as well as the final model that can be used to search additional compound collections and help guide the synthesis of optimized analogs.
Preliminary results with H.E.S. have been very encouraging. In testing against known compound databases, H.E.S. has consistently the majority of known inhibitors of 10 different biological targets after screening an average of 1-10% of a diverse library containing approximately 80,000 molecules.
"Judging by the results we have obtained in our testing, we feel that 'High Efficiency Screening' can not only save researchers great trouble and expense, it can also open up new possibilities for conducting research against diseases that may never justify a full High Throughput Screen by a major drug company", according to Alan H. Katz, Chief Scientific Officer at Hudson Robotics.
About Hudson Robotics:
Hudson Robotics produces laboratory robotics instrumentation, software and systems for automating and accelerating Life Science research, such as drug discovery and genetic research.
Name: Scott VanderWoude
Organization: Hudson Robotics Inc
Address: 10 Stern Ave Springfield, NJ 07081
Phone: (973) 376-7400
For more information, please visit http://www.hudsonrobotics.com
Release ID: 10022